Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Liou, Theodore G ^a   Adler, Frederick R ^b   Keogh, Ruth H ^c   Li, Yanping ^a   Jensen, Judy L ^a   Walsh, William ^a   Packer, Kristyn ^a   Clark, Teresa ^a   Carveth, Holly ^a   Chen, Jun ^a,e   Rogers, Shaunessy L ^a,f   Lane, Christen ^a   Moore, James ^b   Sturrock, Anne ^a   Paine III, Robert ^a   Cox, David R ^d   Hoidal, John R ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

^d NUFFIELD COLLEGE   (United Kingdom)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; RECURRENT DISEASE; RESPIRATORY TRACT INFLAMMATION; SPUTUM EXAMINATION;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; CYSTIC FIBROSIS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HMGB1 PROTEIN; HUMANS; LUNG TRANSPLANTATION; PROGNOSIS; SPUTUM; TREATMENT OUTCOME;

EID: 84866628720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042748     Document Type: Article

References (52)

1. Cystic Fibrosis Foundation Patient Registry 2010 Annual Data Report (2011) Bethesda, Maryland: Cystic Fibrosis Foundation. Available: http://www.cff.org/LivingWithCF/CareCenterNetwork/PatientRegistry/. Accessed 21 Jun 2012.
2. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, et al. ((2001)) Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 153:: 345--52 doi:10.1093/aje/153.4.345.
3. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, et al. ((2003)) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290:: 1749--1756 doi:10.1001/jama.290.13.1749.
4. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, et al. ((1994)) Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis. N Engl J Med 331:: 637--642 doi:10.1056/NEJM199409083311003.
5. Gibson RL, Burns JL, Ramsey BW, ((2003)) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168:: 918--51 doi:10.1164/rccm.200304-505SO.
6. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, et al. ((1995)) Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 152:: 2111--8.
7. Makam M, Diaz D, Laval J, Gernez Y, Conrad CK, et al. ((2009)) Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proc. Natl. Acad. Sci. U.S.A. 106:: 5779--5783 doi:10.1073/pnas.0813410106.
8. Sagel SD, Chmiel JF, Konstan MW, ((2007)) Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 4:: 406--417 doi:10.1513/pats.200703-044BR.
9. Scaffidi P, Misteli T, Bianchi ME, ((2002)) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:: 191--195 doi:10.1038/nature00858.
10. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, et al. ((1999)) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:: 248--251 doi:10.1126/science.285.5425.248.
11. Yang H, Ochani M, Li J, Qiang X, Tanovic M, et al. ((2004)) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101:: 296--301 doi:10.1073/pnas.2434651100.
12. Cystic Fibrosis Foundation (1997) Clinical practice guidelines for cystic fibrosis. Bethesda, Maryland.
13. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society ((1991)) Am Rev Respir Dis. 144:: 1202--18.
14. Hankinson JL, John R Odencrantz, Kathleen B Fedan, ((1999)) Spirometric reference values from a sample of the general U.S. population. Am. J. Respir. Crit. Care Med. 159:: 179--187.
15. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, et al. ((2001)) Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 139:: 359--365 doi:10.1067/mpd.2001.117288.
16. Aaron SD, Ramotar K, Ferris W, Vandemheen K, Saginur R, et al. ((2004)) Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med 169:: 811--815 doi:10.1164/rccm.200309-1306OC.
17. Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, et al. (2012) Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax. Available: http://www.ncbi.nlm.nih.gov/pubmed/22707521. Accessed 20 Jun 2012.
18. Kelly MM, Leigh R, Carruthers S, Horsewood P, Gleich GJ, et al. ((2001)) Increased detection of interleukin-5 in sputum by addition of protease inhibitors. Eur. Respir. J 18:: 685--691.
19. Moser C, Jensen PØ, Pressler T, Frederiksen B, Lanng S, et al. ((2005)) Serum concentrations of GM-CSF and G-CSF correlate with the Th1/Th2 cytokine response in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. APMIS 113:: 400--409 doi:10.1111/j.1600-0463.2005.apm_142.x.
20. Hartl D, Griese M, Kappler M, Zissel G, Reinhardt D, et al. ((2006)) Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J. Allergy Clin. Immunol 117:: 204--211 doi:10.1016/j.jaci.2005.09.023.
21. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, et al. ((2005)) Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353:: 1443--1453 doi:10.1056/NEJMoa051469.
22. Bruscia EM, Zhang P-X, Ferreira E, Caputo C, Emerson JW, et al. ((2009)) Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice. Am. J. Respir. Cell Mol. Biol 40:: 295--304 doi:10.1165/rcmb.2008-0170OC.
23. Hubeau C, Le Naour R, Abély M, Hinnrasky J, Guenounou M, et al. ((2004)) Dysregulation of IL-2 and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients. Clin. Exp. Immunol 135:: 528--534.
24. Yang Y, Trinchieri G, Wilson JM, ((1995)) Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med 1:: 890--893.
25. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, et al. ((2005)) Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J. Immunol 175:: 404--412.
26. Davé SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, et al. ((2009)) Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. Journal of Leukocyte Biology 86:: 633--643 doi:10.1189/jlb.1008662.
27. R Development Core Team (2010) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available: http://www.R-project.org.
28. Venables WN, Ripley BD (2010) Modern Applied Statistics with S. Springer New York.
29. Cox DR, ((1972)) Regression models and life-tables. J R Stat Soc B Met 34:: 187--220 doi:10.2307/2985181.
30. Cox DR, Oakes D (1984) Analysis of survival data. CRC Press.
31. Grambsch PM, Therneau TM, ((1994)) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:: 515--526 doi:10.1093/biomet/81.3.515.
32. Liou TG, Adler FR, Cahill BC, Fitzsimmons SC, Huang D, et al. ((2001)) Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 286:: 2683--9.
33. Liou TG, Adler FR, Cox DR, Cahill BC, ((2007)) Lung transplantation and survival in children with cystic fibrosis. N Engl J Med 357:: 2143--52 doi:10.1056/NEJMoa066359.
34. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, et al. ((2008)) Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am. J. Respir. Crit. Care Med 178:: 822--831 doi:10.1164/rccm.200712-1894OC.
35. Kokkola R, Li J, Sundberg E, Aveberger A-C, Palmblad K, et al. ((2003)) Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 48:: 2052--2058 doi:10.1002/art.11161.
36. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, et al. ((2004)) Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am. J. Respir. Crit. Care Med 170:: 1310--1316 doi:10.1164/rccm.200402-188OC.
37. Park JS, Svetkauskaite D, He Q, Kim J-Y, Strassheim D, et al. ((2004)) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem 279:: 7370--7377 doi:10.1074/jbc.M306793200.
38. Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, et al. ((2010)) Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med 181:: 917--927 doi:10.1164/rccm.200903-0340OC.
39. Liu G, Wang J, Park Y-J, Tsuruta Y, Lorne EF, et al. ((2008)) High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J. Immunol. 181:: 4240--4246.
40. Hreggvidsdottir HS, Ostberg T, Wähämaa H, Schierbeck H, Aveberger A-C, et al. ((2009)) The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol 86:: 655--662 doi:10.1189/jlb.0908548.
41. Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP (n.d.) Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clinical & Experimental Allergy. Available: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2222.2011.03854.x. Accessed 25 Jan 2012.
42. Ballinger MN, Paine R, Serezani CHC, Aronoff DM, Choi ES, et al. ((2006)) Role of granulocyte macrophage colony-stimulating factor during gram-negative lung infection with Pseudomonas aeruginosa. Am. J. Respir. Cell Mol. Biol 34:: 766--774 doi:10.1165/rcmb.2005-0246OC.
43. Saha S, Doe C, Mistry V, Siddiqui S, Parker D, et al. ((2009)) Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD. Thorax 64:: 671--676 doi:10.1136/thx.2008.108290.
44. Saba S, Soong G, Greenberg S, Prince A, ((2002)) Bacterial Stimulation of Epithelial G-CSF and GM-CSF Expression Promotes PMN Survival in CF Airways. Am. J. Respir. Cell Mol. Biol. 27:: 561--567 doi:10.1165/rcmb.2002-0019OC.
45. Carp H, Miller F, Hoidal JR, Janoff A, ((1982)) Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci U S A 79:: 2041--5.
46. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, et al. ((2007)) Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175:: 822--828 doi:10.1164/rccm.200609-1354OC.
47. Hibbs MS, Hoidal JR, Kang AH, ((1987)) Expression of a metalloproteinase that degrades native type V collagen and denatured collagens by cultured human alveolar macrophages. J Clin Invest 80:: 1644--50 doi:10.1172/JCI113253.
48. Sagel SD, Kapsner RK, Osberg I, ((2005)) Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 39:: 224--32 doi:10.1002/ppul.20165.
49. Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR, ((1988)) Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J Clin Invest 82:: 1963--73 doi:10.1172/JCI113816.
50. Rao NV, Wehner NG, Marshall BC, Gray WR, Gray BH, et al. ((1991)) Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. Structural and functional properties. J Biol Chem 266:: 9540--8.
51. Cox DR, Wermuth N, ((2004)) Causality: A statistical view. International Statistical Review 72:: 285--305 doi:10.1111/j.1751-5823.2004.tb00237.x.
52. Peto R, Peto J, ((1972)) Asymptotically Efficient Rank Invariant Test Procedures. Journal of the Royal Statistical Society. Series A (General) 135:: 185--207 doi:10.2307/2344317ips.